Nanobody Conjugates for Targeted Cancer Therapy and Imaging.
Nanobody Conjugates for Targeted Cancer Therapy and Imaging.
复制标题
用于靶向癌症治疗和成像的纳米抗体缀合物
DOI：
10.1177/15330338211010117
复制
发表时间：
2021-01
影响因子：
2.8
通讯作者：
Zhou Q
中科院分区：
文献类型：
--
作者：
Kang W;Ding C;Zheng D;Ma X;Yi L;Tong X;Wu C;Xue C;Yu Y;Zhou Q
常规的基于抗体的靶向癌症治疗是成功治疗癌症的最有希望的途径之一，具有减少对肿瘤细胞周围健康细胞的毒副作用的潜力。然而，抗体的全部潜力由于其大尺寸、低稳定性、缓慢清除和高免疫原性而受到严重限制。或者，最近发现的纳米抗体是最小的天然存在的抗原结合形式，已经显示出解决这些限制的巨大潜力。将纳米抗体与诸如毒素、酶、放射性肽和荧光团的官能团生物缀合可以提高纳米抗体的功效和效力，增强其体内药代动力学，并扩大潜在应用的范围。在此，我们回顾了纳米抗体与常规抗体相比的上级特性，并提供了对用于靶向癌症治疗和成像的纳米抗体缀合物的最新发展的见解。
Conventional antibody-based targeted cancer therapy is one of the most promising avenues of successful cancer treatment, with the potential to reduce toxic side effects to healthy cells surrounding tumor cells. However, the full potential of antibodies is severely limited due to their large size, low stability, slow clearance, and high immunogenicity. Alternatively, recently discovered nanobodies, which are the smallest naturally occurring antigen-binding format, have shown great potential for addressing these limitations. Bioconjugation of nanobodies to functional groups such as toxins, enzymes, radionucleotides, and fluorophores can improve the efficacy and potency of nanobodies, enhance their in vivo pharmacokinetics, and expand the range of potential applications. Herein, we review the superior characteristics of nanobodies in comparison to conventional antibodies and provide insight into recent developments in nanobody conjugates for targeted cancer therapy and imaging.